A first-of-its-kind clinical trial is impacting the ways in which the public approaches brain health. U.S. POINTER is a two-year Alzheimer's Association-funded study that showed healthy behaviors have ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

The Crestwood High School chapter of Future Business Leaders of America participated in the Walk to End Alzheimer’s on Oct.

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...

More than 300 people participated in this year's walk, which raised about $66,000 for the Alzheimer's Association.